Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs offers a wide range of high-quality CD138 CAR-related products, such as CAR vectors, CAR cells, CAR lentivirus, etc. Please browse the following list to find the appropriate products for you.
The CD138 protein, also known as syndecan-1, is a member of the syndecan family that is expressed in both normal plasma cells and MM tumor cells. CD38 is involved in multiple signaling pathways, such as cell-cell and cell-matrix interactions. Importantly, CD38 plays a crucial role in the carcinogenesis processes, especially in cell proliferation, angiogenesis, tumor invasion, and metastasis, making it a potential therapeutic target for many diseases.
Associated Diseases
Creative Biolabs has launched a user-friendly online system for customizing CAR, which provides comprehensive options to meet global customers' various needs. Our robust CAR constructions include classical CAR design, as well as various armored CAR constructions, etc.
Fig.1 Schematic diagram of different CD138 CAR construction.1
Anti-CD138 CAR-T Expression Test
To directly test CAR expression level, Creative Biolabs provides customers with extensive CAR detection reagents (e.g., special target protein, linker-targeted antibodies), as well as various techniques for CAR expression testing, including but not limited to qPCR, WB, and flow cytometry.
Fig.2 The evaluation of CD138 CAR expression of different CD138 CAR-T cells.1
Phenotype Analysis of CD138 CAR-T
Phenotypic analysis of CART cells can provide a variety of information, such as the degree of activation, proliferation capacity, depletion, cell population distribution, etc. Creative Biolabs has developed a comprehensive range of test services for CAR-T characterization, such as expansion tests, exhaustion tests, and cell subgroup analysis.
Fig.3 T sell subgroup (effector T and central memory T subsets) analysis of different CD138 CAR-T cells.1
Anti-CD138 CAR-T Cytokine Release Test
The detection of cytokine production and release illustrate the specificity and effectiveness of CART cells for target cells from the side and provide a reference for further verification. We have developed various appropriate assays for different targets of the CART projects, such as intracellular cytokine tests by flow cytometry, and multiple cytokine arrays.
Fig.4 Cytokine detection of different anti-CD138 CAR-T against CD138+ OPM-2 cells (left panel) or CD138- Raji cells (right panel).1
Anti-CD138 CAR-T In Vitro Cytotoxicity Assay
To evaluate the tumor killing activity of CAR-T cells in vitro, we offer a range of methods for global customers to choose from, such as 51Cr release assay, flow cytometry cytotoxicity test, and real-time dynamic cytotoxicity analysis.
Fig.5 The tumor killing activity of different anti-CD138 CAR-T against CD138+ OPM-2 cells (left panel) or CD138- Raji cells (right panel) detected by 51Cr release assays.1
Anti-CD138 CAR-T Cell Therapy Animal Models
Appropriate animal models and in vivo experimental design are critical for CART efficacy validation. Creative Biolabs provides customers with a wide range of animal models to choose from, as well as several customized in vivo experimental designs.
Efficacy Test of Anti-CD138 CAR-T
With our years of experience in the CAR-T fields, we are committed to developing one-stop CAR-T research services for the treatment of various cancers and other diseases. We offer comprehensive in vivo study services, such as CAR-T efficacy and toxicity study services to ensure the safety of CAR-T therapy.
Fig.6 The antitumor activities of the anti-CD138 CAR-T cells in CD138+ OPM-2 cell line engrafted NSG mouse model detected by BLI.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-LC170 | Anti-CD138 (Indatuximab) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | Indatuximab | Human | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC384 | Anti-CD138 (NI16) h(CD28-CD3ζ,iCasp-9) Self-destruct CAR, pCDCAR1 | Human | NI16 | Mouse | scFv-CD28-41BB-CD27-CD3ζ/iCasp9 | Lentiviral | T cell | ||
| CAR-MZ104 | Anti-CD138 (Indatuximab) scFv h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Indatuximab | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
| CAR-SB-LX0059 | Anti-CD138 (Indatuximab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Indatuximab | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
| XS-0622-ZP3169 | Anti-CD138 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3341 | Anti-CD138 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0822-YF793 | Anti-Human CD138 (XW-793) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-793 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF794 | Anti-Mouse CD138 (XW-794) m(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Mouse | XW-794 | Rabbit | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1715 | Anti-Human CD138 (XW-795) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-795 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1716 | Anti-Human CD138 (XW-796) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-796 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0123-ZP39 | Anti-CD138 (Indatuximab) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | Indatuximab | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP443 | Anti-CD138 (JM11-21) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | JM11-21 | Rabbit | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP694 | Anti-CD138 (BT062) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | BT062 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP697 | Anti-CD138 (XP2) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | XP2 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP39 | Anti-CD138 (Indatuximab scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | Indatuximab | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP443 | Anti-CD138 (JM11-21 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | JM11-21 | Rabbit | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP694 | Anti-CD138 (BT062 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | BT062 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP697 | Anti-CD138 (XP2 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | XP2 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0923-LX73 | Anti-hCD138 (CD28-41BB-CD3ζ) CAR-duplex CTLA4 pCDCAR1 Vector | Human | X9X-42 | scFv-CD28-41BB-CD3ζ-duplex CTLA4 | Lentiviral vector | T cell | CAR-T |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
